Additionally, anti–PD-L1 peptide–conjugated prodrug NPs, which combine PD-L1 blockade with immunogenic cell death, have exhibited efficient tumor targeting and robust antitumor immune responses in breast cancer models (10). Here, CD274 is linked to breast carcinoma.